TABLE 9-1 Characteristics of Hib Vaccines

Vaccine, (producer, trade name)


Protein Carrier

Age of Administration (date of licensure)





(Praxis, b Capsa 1; Lederle, HibImmune; Connaught, HibVAX)



>24 mo (4/85)a (>18 mo if high risk)

PRP-D (Connaught, ProHiBit)


Diphtheria toxoid

18 mo (12/22/87)b 15 mo (12/89)c

HbOC (Lederie-Praxis, Hib-TITER)


CRM197 mutant of Corynebacterium diphtheriae protein

18 mo (12/22/88)d 15 mo (12/89)c 2 mo (10/4/90)e

PRP-OMP (Merck Sharp & Dohme, PedvaxHIB)


Neisseria meningiditis outer membrane protein complex

15 mo (12/89)c 2 mo (12/13/90)f

PRP-T, (Pasteur Merieux-Connaught Vaccins, ActHIB)


Tetanus toxoid

2 mo (3/30/93)g

a Centers for Disease Control (1985).

b Centers for Disease Control (1988).

c Centers for Disease Control (1990a).

d Centers for Disease Control (1989).

e Centers for Disease Control (1990b).

f Centers for Disease Control (1990d).

g Centers for Disease Control and Prevention (1993).

dom demonstrated efficacy of the vaccine when given at ages 2, 3, and 4 months (Booy et al., 1992). Following the widespread distribution and administration of Hib conjugate vaccines, few cases of vaccine failure (a case of Hib disease occurring more than 14 days after the second or third doses) have been reported (Black et al., 1992a; Holmes et al., 1991; Santosham et al., 1992), and postlicensure studies have shown a marked decrease in the incidence of Hib disease in the United States (Adams et al., 1993; Black et al., 1992b; Broadhurst et al., 1993; Centers for Disease Control, 1990c; Murphy et al., 1993b).

The American Academy of Pediatrics and the Advisory Committee on Immunization Practices recommend that conjugate Hib vaccines be administered as two to three doses beginning at age 2 months and then a booster at 12 to 15 months.

The National Academies | 500 Fifth St. N.W. | Washington, D.C. 20001
Copyright © National Academy of Sciences. All rights reserved.
Terms of Use and Privacy Statement